Home›Clinical trials›A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

Recruiting now. Registry record last updated July 10, 2026.

Who can join
Adults 18+, have obesity, BMI 30+.
What you take
NNC0662-0419, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The study runs about 13 months.
What you get
Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 2Sponsor Novo Nordisk A/SDrug NNC0662-0419Class OtherSites 24 USEnrollment target 230

What this study is for

Primary condition: Obesity.

Full scientific study title: A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity.

Who can join

Age18 and upSexAnyBMI30 or higher

Adults 18+, have obesity, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18 years or above at the time of signing the informed consent.
  • Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening.
  • Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.

Key exclusion criteria

  • Known or suspected hypersensitivity to study intervention(s) or related products.
  • Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening.
  • Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus.

Where this trial is enrolling

This trial has 24 sites across 17 states. Contact a site coordinator directly to start screening.

Alabama1 site
  • Chambliss Clinical Trials, LLC
    Montgomery, Alabama
California2 sites
  • FDRC
    Costa Mesa, California
  • Los Angeles Institute for Metabolic Research
    Los Angeles, California
Florida3 sites
  • Encore Medical Research LLC
    Hollywood, Florida
  • South Broward Research LLC
    Miramar, Florida
  • West Orange Endocrinology
    Ocoee, Florida
Illinois2 sites
  • Cedar-Crosse Research Center
    Chicago, Illinois
  • Great Lakes Clinical Trials
    Chicago, Illinois
Indiana1 site
  • Midwest Inst For Clin Res
    Indianapolis, Indiana
Kentucky1 site
  • L-MARC Research Center
    Louisville, Kentucky
Maryland1 site
  • Endo And Metab Cons
    Rockville, Maryland
Missouri1 site
  • StudyMetrix Research LLC
    City of Saint Peters, Missouri
New York1 site
  • Great Lakes Medical Research
    Westfield, New York
North Carolina1 site
  • KDCILM, LLC & Accellacare US, Inc.
    Wilmington, North Carolina
Ohio1 site
  • Family Practice Center of Wadsworth Inc.
    Wadsworth, Ohio
Pennsylvania1 site
  • UPA Ctr Weight and Eating Dis
    Philadelphia, Pennsylvania
Rhode Island1 site
  • Clinical Res Collaborative
    Cumberland, Rhode Island
Tennessee3 sites
  • Holston Medical Group_Bristol
    Bristol, Tennessee
  • Holston Medical Group
    Kingsport, Tennessee
  • Clinical Research Associates
    Nashville, Tennessee
Texas2 sites
  • PlanIt Research, PLLC
    Houston, Texas
  • Pinnacle Clinical Research
    San Antonio, Texas
Virginia1 site
  • National Clin Res Inc.
    Richmond, Virginia
Washington1 site
  • Rainier Clin Res Ctr Inc
    Renton, Washington

Timeline

Started enrolling: June 9, 2026. Expected completion: July 12, 2027. Last updated on ClinicalTrials.gov: July 10, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.